Biora Therapeutics’ BT-600 met all objectives of a Phase I clinical trial, supporting its plan to advance the drug-device combination to Phase Ib tests, according to statement.
- Results confirmed that the NaviCap platform can deliver tofacitinib topically to the colon, with lower peak systemic exposure than with conventional oral delivery
To view the source of this information, click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2024 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.